Media

Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program

Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results And Business Update

Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Aro Biotherapeutics Expands Leadership Team and Plans Move to New Philadelphia Headquarters to Drive Next Phase of Growth

Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Pulmonx Reports Second Quarter 2021 Financial Results

SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer

Fusion Pharmaceuticals Announces FDA Clearance Of IND For FPI-1966, An Investigational Radiopharmaceutical For The Treatment Of Head And Neck And Bladder Cancers Expressing FGFR3